You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
Contributor:
Ghazy, Ehab;
Abdelsalam, Mohamed;
Robaa, Dina;
Pierce, Raymond J.;
Sippl, Wolfgang
Published:
MDPI AG, 2022
Published in:
Pharmaceuticals, 15 (2022) 1, Seite 80
Language:
English
DOI:
10.3390/ph15010080
ISSN:
1424-8247
Origination:
Footnote:
Description:
Schistosomiasis is a major neglected parasitic disease that affects more than 240 million people worldwide and for which the control strategy consists of mass treatment with the only available drug, praziquantel. Schistosomes display morphologically distinct stages during their life cycle and the transformations between stages are controlled by epigenetic mechanisms. The targeting of epigenetic actors might therefore represent the parasites’ Achilles’ heel. Specifically, histone deacetylases have been recently characterized as drug targets for the treatment of schistosomiasis. This review focuses on the recent development of inhibitors for schistosome histone deacetylases. In particular, advances in the development of inhibitors of Schistosoma mansoni histone deacetylase 8 have indicated that targeting this enzyme is a promising approach for the treatment of this infection.